Premium
Efficiency of pretreatment risk stratification systems for prostate cancer in a J apanese population treated with radical prostatectomy
Author(s) -
Koie Takuya,
Mitsuzuka Koji,
Narita Shintaro,
Yoneyama Takahiro,
Kawamura Sadafumi,
Tsuchiya Norihiko,
Tochigi Tatsuo,
Habuchi Tomonori,
Arai Yoichi,
Ohyama Chikara
Publication year - 2015
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.12597
Subject(s) - medicine , prostatectomy , prostate cancer , biochemical recurrence , population , prostate , urology , cancer , oncology , surgery , environmental health
Objective To determine whether the currently available pretreatment risk classification systems are applicable in J apanese prostate cancer patients. Methods Using data obtained from 1264 consecutive patients with prostate cancer treated with radical prostatectomy at four hospitals in J apan, biochemical recurrence‐free survival rates were estimated and compared between the D ' A mico, the N ational I nstitute for H ealth and C linical E xcellence, the C ancer of the P rostate S trategic U rological R esearch E ndeavor, the N ational C omprehensive C ancer N etwork, and the E uropean S ociety of M edical O ncology risk groups by using the K aplan– M eier method and log–rank test. Results The 5‐year biochemical recurrence‐free survival rates in the D ' A mico low‐, intermediate‐, and high‐risk groups were 88.3%, 84.7% and 66.9%, respectively (low and intermediate risk vs high risk, P < 0.001). The 5‐year biochemical recurrence‐free survival rates in the N ational I nstitute for H ealth and C linical E xcellence, N ational C omprehensive C ancer N etwork, and E uropean S ociety of M edical O ncology low‐, intermediate‐ and high‐risk groups were 88.3%, 84.3%, and 60.3%, respectively (low and intermediate risk vs high risk, P < 0.001). The 5‐year biochemical recurrence‐free survival rates in the C ancer of the P rostate S trategic U rological R esearch E ndeavor low‐, intermediate‐, and high‐risk groups were 90%, 83.5% and 60.3%, respectively (low and intermediate risk vs high risk, P < 0.001). Low‐ and intermediate‐risk groups according to any of the risk stratification systems did not show significant differences in biochemical recurrence‐free survival. Conclusion Current risk stratification systems do not discriminate between low‐ and intermediate‐risk groups in the J apanese population. A novel, pretreatment risk stratification system including other prognostic factors is necessary for an adequate prostate cancer risk assessment in the J apanese population.